NCT00425750View on ClinicalTrials.gov

Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Head and Neck Cancer
Interventions
DRUG

bortezomib

1.6 mg/m2 through a vein on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.

DRUG

docetaxel

40 mg/m2 through a vein on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1.

OTHER

laboratory biomarker analysis

Tissue and blood collection.

OTHER

pharmacological study

Blood collection.

Trial Locations (7)

37901

Baptist Regional Cancer Center at Baptist Riverside, Knoxville

38301

West Tennessee Cancer Center at Jackson-Madison County General Hospital, Jackson

38555

Tennessee Plateau Oncology - Crossville, Crossville

42001

Purchase Cancer Group - Paducah, Paducah

42240-2400

Jennie Stuart Medical Center, Hopkinsville

37208-3599

MBCCOP - Meharry Medical College - Nashville, Nashville

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT00425750 - Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Biotech Hunter | Biotech Hunter